{"database": "openregs", "table": "dockets", "rows": [["FDA-2021-P-0567", "FDA", "Requests that the FDA declare that the drug product, Solifenacin Oral Solution, 1 mg/mL is suitable for submission in an Abbreviated New Drug Application", "Nonrulemaking", "2026-06-10T18:15:38Z", "0b00006484b93f5d", null, "CLOSED", null, null, "[\"CLOSED\", \"an ANDA\", \"suitable for submission in\", \"1 mg/mL is\", \"Solifenacin Oral Solution\", \"declare that the drug product\", \"Liqmeds Limited, UK\", \"M A Pharmaceutical Consulting Inc\", \"CDER\", \"Suitability Petition\"]", "CDER", "Requests that the FDA declare that the drug product, Solifenacin Oral Solution, 1 mg/mL is suitable for submission in an ANDA", null, null, "{\"displayProperties\": [{\"name\": \"abstract\", \"label\": \"General Information\", \"tooltip\": \"Describes an agency's specific regulatory action; equivalents: Abstract, Description, Docket Subject, Related To, Summary.\"}, {\"name\": \"generic\", \"label\": \"Docket Item Code\", \"tooltip\": \"An agency specific code that identifies the type of document that established the docket (regulatory action).\"}, {\"name\": \"program\", \"label\": \"Center\", \"tooltip\": \"The agency specific program associated with the docket (regulatory action); equivalents: Docket Item Code,  Location.\"}, {\"name\": \"field2\", \"label\": \"Docket Status\", \"tooltip\": \"Used to Identity that a Docket's Status is Open or Closed\"}, {\"name\": \"shortTitle\", \"label\": \"Short Title\", \"tooltip\": \"A combination of letters and or numbers assigned to an agency's regulatory action for purposes of brevity.\"}], \"keywords\": [\"CLOSED\", \"an ANDA\", \"suitable for submission in\", \"1 mg/mL is\", \"Solifenacin Oral Solution\", \"declare that the drug product\", \"Liqmeds Limited, UK\", \"M A Pharmaceutical Consulting Inc\", \"CDER\", \"Suitability Petition\"], \"modifyDate\": \"2026-06-10T18:15:38Z\", \"dkAbstract\": \"CLOSED\", \"agencyId\": \"FDA\", \"program\": \"CDER\", \"shortTitle\": \"Requests that the FDA declare that the drug product, Solifenacin Oral Solution, 1 mg/mL is suitable for submission in an ANDA\", \"subType2\": null, \"title\": \"Requests that the FDA declare that the drug product, Solifenacin Oral Solution, 1 mg/mL is suitable for submission in an Abbreviated New Drug Application\", \"generic\": \"P\", \"field1\": null, \"docketType\": \"Nonrulemaking\", \"petitionNbr\": null, \"rin\": null, \"organization\": null, \"legacyId\": null, \"subType\": null, \"category\": null, \"field2\": \"CLOSED\", \"effectiveDate\": null, \"objectId\": \"0b00006484b93f5d\"}", "single_get"]], "columns": ["id", "agency_id", "title", "docket_type", "last_modified", "object_id", "rin", "dkabstract", "category", "subtype", "keywords", "program", "short_title", "effective_date", "organization", "attrs_raw", "attr_source"], "primary_keys": ["id"], "primary_key_values": ["FDA-2021-P-0567"], "units": {}, "query_ms": 0.2453300403431058, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}